UK's Allergy Therapeutics FY revenue beats on Grassmuno launch

Allergy Therapeutics

29/07/2026 07:14

Overview
UK allergy immunotherapy firm's FY revenue rose 9% to £59.9 mln
H2 revenue growth accelerated to over 12% after Grassmuno launch in Germany
Company ended year with £24.2 mln cash after new funding and loan repayments

Outlook
Company expects double digit revenue growth for year ending 30 June 2027
Allergy Therapeutics sees sales momentum accelerating with full high season of Grassmuno availability
Company says end of German TAV programme in October 2026 supports future growth

Result Drivers
GRASSMUNO LAUNCH - Launch of Grassmuno in Germany in H2 supported accelerated revenue growth, despite missing most of the peak treatment season
REGISTERED PRODUCTS - Growth in Germany driven by registered product portfolio, including Pollinex, Venomil and Grassmuno, as unregistered products phased out
SPAIN GROWTH - Strong revenue growth in Spain, the Group’s second largest market, up 12% on a constant currency basis

Company press release: ID:nRSc2593Oa

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
FY Revenue
Miss
GBP 59.90 mln
GBP 63 mln (1 Analyst)

Analyst Coverage
The one available analyst rating on the shares is "strong buy"
The average consensus recommendation for the pharmaceuticals peer group is "buy."
Wall Street's median 12-month price target for Allergy Therapeutics PLC is GBp13.00, about 141.6% above its July 28 closing price of GBp5.38

Reuters Recommended Reads
July 28 - Italy's Recordati H1 revenue rises 6.6% on rare diseases segment growth
July 28 - Germany's Medios cuts 2026 EBITDA outlook on pharma supply price pressure
July 27 - AstraZeneca profit beat, bullish tone ease worries over drug pipeline

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)